Cytokines interleukin (IL) 12 and 23 play critical roles in linking innate and adaptive immune responses. They are members of heterodimeric cytokines, sharing a subunit p40. Although IL12/23 p40 is mainly induced in macrophages and dendritic cells (DCs) after stimulation with microbial Toll-like receptor ligands, methods to monitor the cells that produce IL12/23 p40 in vivo are limited. Recently, the mouse model to track p40-expressing cells with fluorescent reporter, yellow fluorescent protein, has been developed. Macrophages and DCs from these mice faithfully reported p40 induction using the fluorescent marker. Here we took advantage of these reporter mice to screen bio-compounds for p40-inducing activity. After screening hundreds of compounds, we found several extracts inducing IL12/23 p40 gene expression. Treatment of DCs with these extracts induced the expression of MHC class II and co-stimulatory molecules, which implies that these might be useful as adjuvants. Next, the in vivo target immune cells of candidate compounds were examined. The reporter system can be useful to identify cells producing IL12 or IL23 in vivo as well as in vitro. Thus, our cytokine reporter system proved to be a valuable reagent for screening for immunostimulatory molecules and identification of target cells in vivo.

Download full-text PDF

Source

Publication Analysis

Top Keywords

il12/23 p40
12
cytokine reporter
8
reporter system
8
cells
6
p40
5
reporter mouse
4
mouse system
4
system screening
4
screening novel
4
il12/23
4

Similar Publications

Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease.

Front Immunol

August 2024

Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China.

IBD (inflammatory bowel disease) is a chronic inflammatory disease of the gastrointestinal tract with increasing incidence worldwide. Multiple factors, such as genetic background, environmental and luminal factors, and mucosal immune dysregulation, have been implicated in the cause of IBD, although the cause of the disease remains unknown. IL-12 and IL-23 and their downstream signaling pathways participate in the pathogenesis of inflammatory bowel disease.

View Article and Find Full Text PDF

Inflammatory bowel disease (IBD), which includes both Crohn disease and ulcerative colitis, is a relapsing inflammatory disease of the gastrointestinal tract. Long-term chronic inflammatory conditions elevate the patient's risk of colorectal cancer (CRC). Currently, diagnosis requires endoscopy with biopsy.

View Article and Find Full Text PDF

Background: The improvement of colitis symptoms by treatment with IL-12/23 p40 neutralizing antibody should increase the muscle mass and the function of the sarcopenia phenotype.

Methods: An experimental colitis model was induced by oral administration of 2% dextran sulfate sodium (DSS) for 7 days. During induction of colitis, IL-12/23 p40 neutralizing antibody was injected twice on Days 3 and 5.

View Article and Find Full Text PDF

As our comprehension of the pathogenic mechanisms of inflammatory bowel disease (IBD) increases, the therapeutic armamentarium for its treatment can expand, and novel target therapies join the treatment pipeline. Interleukin (IL)-12 and IL23 are two key cytokines responsible for promoting and perpetuating bowel inflammation in IBD. Ustekinumab is a monoclonal antibody directed against the shared p40 subunit of both cytokines, and it was recently approved for the treatment of ulcerative colitis (UC).

View Article and Find Full Text PDF
Article Synopsis
  • Psoriasis affects about 2% of children in Europe, with most cases manageable through topical corticosteroid treatments, while more severe cases may need phototherapy or systemic drugs that can have serious side effects.
  • Over the past 15 years, several biologic treatments have been developed for moderate-to-severe plaque psoriasis, starting with etanercept and later including adalimumab, ustekinumab, secukinumab, and ixekizumab, which show better efficacy and safety compared to traditional therapies.
  • Experts recommend ustekinumab, secukinumab, and ixekizumab as first-line treatments for moderate-to-severe psoriasis in children and adolescents due to their excellent outcomes and lower risk of adverse effects.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!